par Le Mercier, Marie ;Mathieu, Véronique ;Haibe-Kains, Benjamin ;Bontempi, Gianluca ;Mijatovic, Tatjana ;Decaestecker, Christine ;Kiss, Robert ;Lefranc, Florence
Référence Journal of neuropathology and experimental neurology, 67, 5, page (456-469)
Publication Publié, 2008-05
Référence Journal of neuropathology and experimental neurology, 67, 5, page (456-469)
Publication Publié, 2008-05
Article révisé par les pairs
Résumé : | Galectin (Gal) 1 is a hypoxia-regulated proangiogenic factor that also directly participates in glioblastoma cell migration. To determine how Gal-1 exerts its proangiogenic effects, we investigated Gal-1 signaling in the human Hs683 glioblastoma cell line. Galectin 1 signals through the endoplasmic reticulum transmembrane kinase/ribonuclease inositol-requiring 1alpha, which regulates the expression of oxygen-regulated protein 150. Oxygen-regulated protein 150 controls vascular endothelial growth factor maturation. Galectin 1 also modulates the expression of 7 other hypoxia-related genes (i.e. CTGF, ATF3, PPP1R15A, HSPA5, TRA1, and CYR61) that are implicated in angiogenesis. Decreasing Gal-1 expression in Hs683 orthotopic xenografts in mouse brains by siRNA administration impaired endoplasmic reticulum stress and enhanced the therapeutic benefits of the proautophagic drug temozolomide. These results suggest that decreasing Gal-1 expression (e.g. through brain delivery of nonviral infusions of anti-Gal-1 siRNA in patients) can represent an additional therapeutic strategy for glioblastoma. |